There are approximately 8000 rare diseases in the world and many of these are chronic, life-threatening conditions.1 To fight these elusive illnesses, the medical community focuses on developing specialised medications known as orphan drugs.
Originating from the United States Orphan Drug Act (ODA) in 1983, the term “Orphan Drug” reflects the lack of attention and the investment necessary for their development.
The Orphan Drug Act and similar legislations aim to progress the development of drugs for rare diseases by offering various incentives to drug manufacturers.
Despite government support, orphan drugs have been priced significantly higher than non-orphan ones owing to the inherent complexities and high costs of production.2
Yet, there are other barriers to patients receiving life-saving treatments.3 One that’s frequently overlooked is the complexity of transporting these highly sensitive drugs from the lab to the end user.
If manufacturers cannot ensure safe, cost-effective delivery, then access to these rare treatments will remain out of reach for many patients. Efficient logistics must take centre stage.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.